Skip to main
PAVM
PAVM logo

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc is positioned for substantial growth within the medical technology sector, with its diverse offerings in Diagnostics, Medical Devices, and Digital Health. The company presents an attractive current valuation that aligns with its potential for significant upside, despite the inherent risks associated with early-stage commercialization. Analysts anticipate substantial revenue growth for key products like EsoGuard and the Veris Cancer Care Platform, expected to emerge prominently in 2025 and 2026.

Bears say

PAVmed Inc reported a pro forma net loss of $0.8 million, translating to an earnings per share (EPS) of $(0.05), which was significantly better than the expected loss range of $(0.13) to $(0.25). However, the company experienced a decline in the number of EsoGuard tests processed, dropping from 3,034 in Q1 to 2,756 in Q2, indicating a negative trend in product usage and demand. Additionally, multiple risks impacting the company's financial performance include liquidity concerns, challenges in demonstrating product effectiveness, regulatory hurdles, commercialization issues, and varying macroeconomic conditions, all of which contribute to a cautious outlook on PAVmed's stock.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.